Inhibitory Effect of IVIG on IL-17 Production by Th17 Cells is Independent of Anti-IL-17 Antibodies in the Immunoglobulin Preparations

[1]  S. Kaveri,et al.  Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. , 2012, The American journal of pathology.

[2]  Yasaman Nouhi,et al.  Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. , 2012, The Journal of allergy and clinical immunology.

[3]  S. Kaveri,et al.  Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease , 2012, The Journal of Rheumatology.

[4]  S. Kaveri.  [Mechanisms of action of intravenous immunoglobulins]. , 2012, Bulletin de l'Academie nationale de medecine.

[5]  S. Kaveri,et al.  Comparison of different IVIg preparations on IL-17 production by human Th17 cells. , 2011, Autoimmunity reviews.

[6]  S. Kaveri,et al.  Intravenous immunoglobulin therapy in rheumatic diseases , 2011, Nature Reviews Rheumatology.

[7]  S. Kaveri,et al.  Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. , 2011, The Journal of allergy and clinical immunology.

[8]  M. Ballow.  The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. , 2011, The Journal of allergy and clinical immunology.

[9]  S. Kaveri,et al.  Autoimmunity as a Predisposition for Infectious Diseases , 2010, PLoS pathogens.

[10]  J. Ravetch,et al.  A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs , 2010, Journal of Clinical Immunology.

[11]  S. Kaveri,et al.  Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells , 2010, Journal of Clinical Immunology.

[12]  A. Lazarus.  Adoptive-Transfer Effects of Intravenous Immunoglobulin in Autoimmunity , 2010, Journal of Clinical Immunology.

[13]  R. Lemieux,et al.  Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. , 2010, Blood.

[14]  A. Fischer,et al.  Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I , 2010, The Journal of experimental medicine.

[15]  Jagadeesh Bayry,et al.  Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. , 2009, Trends in pharmacological sciences.

[16]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[17]  D. Scott,et al.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.

[18]  Y. Shoenfeld,et al.  What is the contents of the magic draft IVIg? , 2008, Autoimmunity reviews.

[19]  S. Kaveri,et al.  Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. , 2008, Blood.

[20]  Y. Shoenfeld,et al.  Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function , 2007, The Journal of Immunology.

[21]  S. Kaveri,et al.  Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. , 2003, Blood.

[22]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.